SE0200843D0 - Chemical compounds - Google Patents

Chemical compounds

Info

Publication number
SE0200843D0
SE0200843D0 SE0200843A SE0200843A SE0200843D0 SE 0200843 D0 SE0200843 D0 SE 0200843D0 SE 0200843 A SE0200843 A SE 0200843A SE 0200843 A SE0200843 A SE 0200843A SE 0200843 D0 SE0200843 D0 SE 0200843D0
Authority
SE
Sweden
Prior art keywords
chemical compounds
compound
ccr3
chemokine
variables
Prior art date
Application number
SE0200843A
Other languages
English (en)
Inventor
Hitesh Sanganee
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0200843A priority Critical patent/SE0200843D0/sv
Publication of SE0200843D0 publication Critical patent/SE0200843D0/sv
Priority to EP03708798A priority patent/EP1487817B1/en
Priority to AT03708798T priority patent/ATE397599T1/de
Priority to JP2003576426A priority patent/JP2005526089A/ja
Priority to AU2003212769A priority patent/AU2003212769A1/en
Priority to DE60321452T priority patent/DE60321452D1/de
Priority to ES03708798T priority patent/ES2305447T3/es
Priority to US10/508,332 priority patent/US7482363B2/en
Priority to PCT/SE2003/000442 priority patent/WO2003078421A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
SE0200843A 2002-03-19 2002-03-19 Chemical compounds SE0200843D0 (sv)

Priority Applications (9)

Application Number Priority Date Filing Date Title
SE0200843A SE0200843D0 (sv) 2002-03-19 2002-03-19 Chemical compounds
EP03708798A EP1487817B1 (en) 2002-03-19 2003-03-17 Piperidine derivatives useful as modulators of chemokine receptor activity
AT03708798T ATE397599T1 (de) 2002-03-19 2003-03-17 Als modulatoren der chemokinrezeptoraktivität geeignete piperidinderivate
JP2003576426A JP2005526089A (ja) 2002-03-19 2003-03-17 ケモカイン受容体活性のモジュレーターとして有用なピペリジン誘導体
AU2003212769A AU2003212769A1 (en) 2002-03-19 2003-03-17 Piperidine derivatives useful as modulators of chemokine receptor activity
DE60321452T DE60321452D1 (de) 2002-03-19 2003-03-17 Als modulatoren der chemokinrezeptoraktivität geeignete piperidinderivate
ES03708798T ES2305447T3 (es) 2002-03-19 2003-03-17 Derivados de piperidina utiles como moduladores de la actividad del receptor de quimoquina.
US10/508,332 US7482363B2 (en) 2002-03-19 2003-03-17 Piperidine derivatives useful as modulators of chemokine receptor activity
PCT/SE2003/000442 WO2003078421A1 (en) 2002-03-19 2003-03-17 Piperidine derivatives useful as modulators of chemokine receptor activity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0200843A SE0200843D0 (sv) 2002-03-19 2002-03-19 Chemical compounds

Publications (1)

Publication Number Publication Date
SE0200843D0 true SE0200843D0 (sv) 2002-03-19

Family

ID=20287325

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0200843A SE0200843D0 (sv) 2002-03-19 2002-03-19 Chemical compounds

Country Status (9)

Country Link
US (1) US7482363B2 (sv)
EP (1) EP1487817B1 (sv)
JP (1) JP2005526089A (sv)
AT (1) ATE397599T1 (sv)
AU (1) AU2003212769A1 (sv)
DE (1) DE60321452D1 (sv)
ES (1) ES2305447T3 (sv)
SE (1) SE0200843D0 (sv)
WO (1) WO2003078421A1 (sv)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR033517A1 (es) * 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
ES2258642T3 (es) 2001-07-02 2006-09-01 Astrazeneca Ab Derivados de piperidina utiles como moduladores de la actividad del receptor de quimiocina.
GB0120461D0 (en) 2001-08-22 2001-10-17 Astrazeneca Ab Novel compounds
GB0122503D0 (en) 2001-09-18 2001-11-07 Astrazeneca Ab Chemical compounds
US6949590B2 (en) * 2002-01-10 2005-09-27 University Of Washington Hydrogels formed by non-covalent linkages
SE0200844D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
SE0202838D0 (sv) * 2002-09-24 2002-09-24 Astrazeneca Ab Chemical compounds
SE0300957D0 (sv) * 2003-04-01 2003-04-01 Astrazeneca Ab Chemical compounds
SE0400925D0 (sv) * 2004-04-06 2004-04-06 Astrazeneca Ab Chemical compounds
TW200722419A (en) * 2005-05-27 2007-06-16 Astrazeneca Ab Chemical compounds
EP1888527A1 (en) * 2005-05-27 2008-02-20 AstraZeneca AB Piperidines for the treatment of chemokine mediated diseases
WO2007011293A1 (en) 2005-07-21 2007-01-25 Astrazeneca Ab Novel piperidine derivatives
WO2010129351A1 (en) 2009-04-28 2010-11-11 Schepens Eye Research Institute Method to identify and treat age-related macular degeneration
MX337662B (es) 2010-10-06 2016-03-14 Glaxosmithkline Llc Derivados de bencimidazol como inhibidores de cinasa pi3.

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1250719A (sv) 1969-03-19 1971-10-20
US4556660A (en) 1982-07-12 1985-12-03 Janssen Pharmaceutica N.V. N-(Bicyclic heterocyclyl)-4-piperidinamines
DK139684A (da) 1983-04-11 1984-10-12 Janssen Pharmaceutica Nv N-aryl-alpha-amino-carboxamider
US4634704A (en) 1983-10-06 1987-01-06 Janssen Pharmaceutica, N.V. Anti-allergic five membered heterocyclic ring containing N-(bicyclic heterocycyl)-4-piperidinamines
US4695575A (en) 1984-11-13 1987-09-22 Janssen Pharmaceutica, N.V. 4-[(bicycle heterocyclyl)-methyl and -hetero]-piperidines
PH23995A (en) 1984-01-09 1990-02-09 Janssen Pharmaceutica Nv 4((bicycle heterocyclyl)-methyl and hetero)piperidines
US4588722A (en) 1984-01-09 1986-05-13 Janssen Pharmaceutica N.V. N-(4-piperidinyl) bicyclic condensed 2-imidazolamine derivatives
EP0612313A1 (en) * 1991-11-14 1994-08-31 Glaxo Group Limited Piperidine acetic acid derivatives as inhibitors of fibrinogen-dependent blood platelet aggregation
GB9319534D0 (en) 1993-09-22 1993-11-10 Boots Co Plc Therapeutic agents
US5889006A (en) 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5696267A (en) 1995-05-02 1997-12-09 Schering Corporation Substituted oximes, hydrazones and olefins as neurokinin antagonists
AU5966096A (en) * 1995-06-09 1997-01-09 Eli Lilly And Company Methods of treating cold and allergic rhinitis
TW531537B (en) 1995-12-27 2003-05-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives
EP0912515B1 (en) 1996-07-10 2002-11-13 Schering Corporation 1,4-di-substituted piperidines as muscarinic antagonists
US5952349A (en) 1996-07-10 1999-09-14 Schering Corporation Muscarinic antagonists for treating memory loss
EP0821954A1 (en) 1996-08-01 1998-02-04 Eli Lilly And Company Method for treating mental retardation
US5977138A (en) 1996-08-15 1999-11-02 Schering Corporation Ether muscarinic antagonists
ES2241053T3 (es) 1996-08-15 2005-10-16 Schering Corporation Eteres antagonistas muscarinicos.
SK285631B6 (sk) 1996-09-10 2007-05-03 Dr. Karl Thomae Gmbh Modifikované aminokyseliny, farmaceutický prostriedok s ich obsahom a ich použitie
WO1999004794A1 (en) 1997-07-25 1999-02-04 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
WO1999037304A1 (en) 1998-01-27 1999-07-29 Aventis Pharmaceuticals Products Inc. SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS
CA2319781A1 (en) 1998-02-02 1999-08-05 Liping Wang Cyclic amine modulators of chemokine receptor activity
TWI245763B (en) 1998-04-02 2005-12-21 Janssen Pharmaceutica Nv Biocidal benzylbiphenyl derivatives
WO1999055324A1 (en) 1998-04-27 1999-11-04 Smithkline Beecham Corporation Ccr-3 receptor antagonists
IL138568A0 (en) 1998-04-28 2001-10-31 Dainippon Pharmaceutical Co 1-[(1-substituted-4-piperidinyl) methyl] -4- piperidine derivative, process for the preparation thereof, pharmaceutical composition containing the same and intermediate therefor
US6066636A (en) 1998-06-30 2000-05-23 Schering Corporation Muscarinic antagonists
KR20010053254A (ko) 1998-06-30 2001-06-25 둘락 노먼 씨. 무스카린성 길항제
GB9919776D0 (en) 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
JP2003529531A (ja) 1998-11-25 2003-10-07 アヴェンティス ファーマシューティカルズ インコーポレイテッド 置換オキソアザへテロシクリルＸａ因子阻害剤
EP1140834A1 (en) * 1998-12-18 2001-10-10 Du Pont Pharmaceuticals Company Heterocyclic piperidines as modulators of chemokine receptor activity
US6387930B1 (en) 1999-05-04 2002-05-14 Schering Corporation Piperidine derivatives useful as CCR5 antagonists
JP3894729B2 (ja) 1999-05-04 2007-03-22 シェーリング コーポレイション Ｃｃｒ５アンタゴニストとして有用なピペラジン誘導体
SE9902551D0 (sv) 1999-07-02 1999-07-02 Astra Pharma Prod Novel compounds
AU773227B2 (en) 1999-07-28 2004-05-20 Aventis Pharmaceuticals Inc. Substituted oxoazaheterocyclyl compounds
US6294554B1 (en) * 1999-09-22 2001-09-25 Schering Corporation Muscarinic antagonists
IT1307809B1 (it) * 1999-10-21 2001-11-19 Menarini Ricerche Spa Composti monociclici basici ad azione nk-2 antagonista, processi difabbricazione e formulazioni che li contengono.
AR033517A1 (es) * 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
GB0013060D0 (en) 2000-05-31 2000-07-19 Astrazeneca Ab Chemical compounds
WO2002018335A1 (fr) 2000-08-28 2002-03-07 Yamanouchi Pharmaceutical Co., Ltd. Derives d'amine cyclique
GB0021670D0 (en) 2000-09-04 2000-10-18 Astrazeneca Ab Chemical compounds
GB0104050D0 (en) 2001-02-19 2001-04-04 Astrazeneca Ab Chemical compounds
GB2373186A (en) 2001-02-23 2002-09-18 Astrazeneca Ab Pharmaceutical combinations of a CCR3 antagonist and a compound which is usefulreatment of asthma, allergic disease or inflammation
WO2002072570A2 (en) 2001-03-13 2002-09-19 Schering Corporation Non-imidazole compounds as histamine h3 antagonists
PT1373256E (pt) 2001-03-29 2005-11-30 Schering Corp Antagonistas dos ccr5 uteis para tratamento de sida
GB0107907D0 (en) 2001-03-29 2001-05-23 Smithkline Beecham Plc Novel compounds
GB0108876D0 (en) 2001-04-09 2001-05-30 Novartis Ag Organic Compounds
KR20040015191A (ko) 2001-04-27 2004-02-18 미쯔비시 웰 파마 가부시키가이샤 신규 벤질피페리딘 화합물
ES2258642T3 (es) * 2001-07-02 2006-09-01 Astrazeneca Ab Derivados de piperidina utiles como moduladores de la actividad del receptor de quimiocina.
GB0117899D0 (en) * 2001-07-23 2001-09-12 Astrazeneca Ab Chemical compounds
GB0120461D0 (en) 2001-08-22 2001-10-17 Astrazeneca Ab Novel compounds
AR036366A1 (es) 2001-08-29 2004-09-01 Schering Corp Derivados de piperidina utiles como antagonistas de ccr5, composiciones farmaceuticas, el uso de dichos derivados para la fabricación de un medicamento y un kit
JP2003081937A (ja) 2001-09-07 2003-03-19 Bayer Ag ベンゼンスルホンアミド誘導体
GB0122503D0 (en) 2001-09-18 2001-11-07 Astrazeneca Ab Chemical compounds
SE0200844D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
US6696468B2 (en) 2002-05-16 2004-02-24 Dainippon Pharmaceutical Co., Ltd. (s)-4-amino-5-chloro-2-methoxy-n-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor
SE0202838D0 (sv) * 2002-09-24 2002-09-24 Astrazeneca Ab Chemical compounds
SE0300850D0 (sv) 2003-03-25 2003-03-25 Astrazeneca Ab Chemical compounds
SE0300957D0 (sv) 2003-04-01 2003-04-01 Astrazeneca Ab Chemical compounds
SE0301368D0 (sv) * 2003-05-09 2003-05-09 Astrazeneca Ab Chemical compounds
BRPI0411414A (pt) 2003-06-13 2006-07-25 Schering Ag derivados de quinolil amida como antagonistas de cdr-5
SE0400925D0 (sv) 2004-04-06 2004-04-06 Astrazeneca Ab Chemical compounds
TW200722419A (en) 2005-05-27 2007-06-16 Astrazeneca Ab Chemical compounds
EP1888527A1 (en) 2005-05-27 2008-02-20 AstraZeneca AB Piperidines for the treatment of chemokine mediated diseases
WO2007011293A1 (en) 2005-07-21 2007-01-25 Astrazeneca Ab Novel piperidine derivatives

Also Published As

Publication number Publication date
US7482363B2 (en) 2009-01-27
ES2305447T3 (es) 2008-11-01
WO2003078421A1 (en) 2003-09-25
DE60321452D1 (de) 2008-07-17
US20050182094A1 (en) 2005-08-18
JP2005526089A (ja) 2005-09-02
EP1487817B1 (en) 2008-06-04
ATE397599T1 (de) 2008-06-15
AU2003212769A1 (en) 2003-09-29
EP1487817A1 (en) 2004-12-22

Similar Documents

Publication Publication Date Title
SE0301368D0 (sv) Chemical compounds
SE0202838D0 (sv) Chemical compounds
NO20055068L (no) Kjemiske forbindelser
TW200726767A (en) Chemical compounds 2
SE0300850D0 (sv) Chemical compounds
MX2009007231A (es) Compuestos quimicos 637:piridopirimidindionas como inhibidores de la fosfodiesterasa 4.
MY128441A (en) Bipiperidine derivatives as modulators of ccr3 activity and as h1 antogonists
NO20055649L (no) Substituert dihydrokinazolin med antiviale egenskaper
ATE381539T1 (de) Dipeptidylpeptidase-hemmer zur behandlung von diabetes
ATE433447T1 (de) Pyrimiidinverbindungen
SE0200843D0 (sv) Chemical compounds
EP1794120A4 (en) peptidase
CO5690637A2 (es) Tiazol-(bi) cicloalquil-carboxanilidas
SE0200844D0 (sv) Chemical compounds
ATE364043T1 (de) Pyrazolo-pyridine für die behandlung von herpes- ansteckungen
TW200745106A (en) Chemical compounds
WO2003106450A8 (de) Phenylaminopyrimidine und ihre verwendung als rho-kinase inhibitoren
NO20043016L (no) 6-aminomorfinan-derivater, fremgangsmate for fremstilling og anvendelse derav
TW200800942A (en) Chemical compounds
TW200722419A (en) Chemical compounds
SE0400925D0 (sv) Chemical compounds
NO20032406L (no) Anvendelse av 1-fenyl-3-dimetylaminopropanforbindelser for behandling av urininkontinens
DE602004021363D1 (de) Imidazotriazin verbindungen zur behandlung von krebserkrankungen
WO2005040129A3 (en) Ccr3 receptor antagonists
NO20053562L (no) Nye aminobenzofenonforbindelser